Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Why Doximity Stock Skyrocketed Higher Today
According to data provided by S&P Global Market Intelligence, the "Bloomberg platform for medical professionals," Doximity (DOCS 33.69%), saw its shares spike 34% as of 11:20 a.m. ET Friday.
Doximity shares pop 30% on revenue beat, rosy guidance
Doximity shares ripped higher Friday, a day after reporting fiscal third-quarter results that beat expectations for revenue and guidance. Analysts called it a "statement type of quarter" for the company.
Doximity, Inc. (DOCS) Q3 2025 Earnings Call Transcript
Doximity, Inc. (DOCS) Q3 2025 Earnings Call Transcript
Doximity (DOCS) Q3 Earnings and Revenues Top Estimates
Doximity (DOCS) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.29 per share a year ago.
Doximity shares soar 21% after company beats on revenue, raises fiscal year guidance
Doximity reported third-quarter fiscal 2025 results that beat analysts' expectations for revenue and guidance. The company's revenue increased 25% to $168.6 million in its third quarter.
Doximity Surpasses EPS, Revenue Goals
Doximity (DOCS 0.21%), a digital platform for U.S. medical professionals, released its fiscal third-quarter earnings on Feb. 6, 2025. The company reported impressive results, surpassing both analyst forecasts and its own guidance.
Dr Martens recovery plan to be tested in forthcoming update
Dr Martens PLC (LSE:DOCS) shares have been rising recently, a rare event since the iconic boot maker listed in 2021. New chief executive Ije Nwokorie, ex-Wolff Olins and Apple, came with a lot of goodwill and that has helped but next week's update will be a more serious test.
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution
Upgraded Doximity to a buy rating due to recent share price pullback, stronger engagement metrics, and deeper client relationships, creating a compelling entry point. DOCS reported 20% y/y revenue growth in 2Q25, surpassing management's guidance, with increased user adoption and higher revenue per user driving performance. The adoption of AI-driven tools and expanded Client Portal access are enhancing the Company's value proposition, leading to higher engagement and better-targeted advertising for pharma clients.
Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note
Doximity (DOCS) closed the most recent trading day at $58.18, moving +0.61% from the previous trading session.
This Health Care Software Firm Nears Buy Point After Whopping 101% Year-To-Date Gain
Doximity stock jumped over 34% following its most recent earnings report on Nov. 11. Now, shares are nearing a buy point.
Doximity initiated with an Equal Weight at Stephens
Stephens initiated coverage of Doximity with an Equal Weight rating and $55 price target. Doximity runs the "leading digital platform for doctors" and is executing on multiple avenues of growth, though it has "settled into a low-to-mid-teens growth profile," the analyst tells investors. The firm believes the current valuation presumes revenue growth will re-accelerate based on the self-serve marketplace increasing up-sell/cross-sell and new product successes and while it sees potential for EBITDA outperformance, the firm lacks "the visibility and conviction to model above-consensus growth and further margin expansion" as a base case, the analyst tells investors.
